MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.81
+2.36
+2.93%
Closed 16:00 09/22 EDT
OPEN
80.53
PREV CLOSE
80.45
HIGH
82.86
LOW
77.56
VOLUME
341.51K
TURNOVER
--
52 WEEK HIGH
91.77
52 WEEK LOW
31.99
MARKET CAP
5.02B
P/E (TTM)
-15.8679
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer
Ms. Dier will start in new role in November 2020NOVATO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced
GlobeNewswire · 09/02 13:01
New finance chief for Ultragenyx
Ultragenyx Pharmaceutical (RARE) has appointed Mardi C. Dier as EVP and CFO, effective November 2, 2020.Ms. Dier will succeed Ms. Sharp, who will remain as CFO until November and will
Seekingalpha · 09/02 12:10
Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer
NOVATO, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Ernie Meyer as Executive
GlobeNewswire · 09/01 13:31
Ultragenyx (RARE) Up 10.4% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 08/29 16:32
Ultragenyx Pharmaceutical, IBD Stock Of The Day, Targets Ultra-Rare Diseases
Investor's Business Daily · 08/27 22:10
A Quick Analysis On Ultragenyx Pharmaceutical's (NASDAQ:RARE) CEO Salary
Simply Wall St. · 08/19 20:22
Did Hedge Funds Make The Right Call On Ultragenyx Pharmaceutical Inc (RARE) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 08/10 16:43
Ultragenyx to Present at Upcoming Investor Conferences
NOVATO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced th
GlobeNewswire · 08/04 12:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RARE. Analyze the recent business situations of Ultragenyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RARE stock price target is 85.56 with a high estimate of 99.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 270
Institutional Holdings: 68.80M
% Owned: 113.55%
Shares Outstanding: 60.59M
TypeInstitutionsShares
Increased
65
5.67M
New
48
553.33K
Decreased
65
3.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.12%
Key Executives
Chairman/Independent Director
Daniel Welch
President/Chief Executive Officer/Director
Emil Kakkis
Chief Human Resource Officer/Executive Vice President
Ernie Meyer
Executive Vice President/General Counsel
Karah Parschauer
Executive Vice President
Erik Harris
Executive Vice President
Dennis Huang
Executive Vice President
Thomas Kassberg
Executive Vice President
John Pinion
Other
Camille Bedrosian
Independent Director
William Aliski
Independent Director
Deborah Dunsire
Independent Director
Lars Ekman
Independent Director
Matthew Fust
Independent Director
Michael Narachi
Independent Director
Clay Siegall
Independent Director
Shehnaaz Suliman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RARE
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.